Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trialResearch in context

Summary: Background: Primary aldosteronism (PA) is caused by autonomous aldosterone overproduction and characterised by uncontrolled hypertension. There are currently no treatments that target aldosterone synthesis. We evaluated the safety and efficacy of a novel aldosterone synthase inhibitor, dex...

Cijeli opis

Bibliografski detalji

Glavni autori:	Paolo Mulatero, Gregoire Wuerzner, Michael Groessl, Elisa Sconfienza, Aikaterini Damianaki, Vittorio Forestiero, Bruno Vogt, Hans Brunner, Teresa Gerlock, Ronald Steele, Christoph Schumacher
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-05-01
Serija:	EClinicalMedicine
Teme:	Aldosterone Renin Aldosterone synthase inhibition Primary aldosteronism Hypertension
Online pristup:	http://www.sciencedirect.com/science/article/pii/S258953702400155X
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!